NASDAQ:TTNP Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free TTNP Stock Alerts $6.94 0.00 (0.00%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$6.94▼$6.9450-Day Range$6.34▼$7.3452-Week Range$5.00▼$16.59Volume320 shsAverage Volume1,717 shsMarket Capitalization$6.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends Get Titan Pharmaceuticals alerts: Email Address Ad Priority GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Titan Pharmaceuticals Stock (NASDAQ:TTNP)Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.Read More TTNP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TTNP Stock News HeadlinesJune 11 at 2:54 AM | americanbankingnews.comTitan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.comMay 16, 2024 | investorplace.comTTNP Stock Earnings: Titan Pharmaceuticals Reported Results for Q4 2023May 16, 2024 | investorplace.comTTNP Stock Earnings: Titan Pharmaceuticals Reported Results for Q1 2024May 3, 2024 | reuters.comIndia's Titan misses Q4 profit view as surging gold prices dampen demandMarch 2, 2024 | uk.investing.comTitan Pharmaceuticals Inc (TTNP)February 20, 2024 | au.finance.yahoo.comTitan Pharmaceuticals, Inc. (TN70.F)February 3, 2024 | morningstar.comTitan Pharmaceuticals Inc TTNPJanuary 26, 2024 | finanznachrichten.deTitan Pharmaceuticals, Inc.: Titan Pharmaceuticals Fully Compliant With NASDAQ Listing CriteriaJanuary 25, 2024 | finance.yahoo.comTitan Pharmaceuticals Fully Compliant With NASDAQ Listing CriteriaJanuary 10, 2024 | benzinga.comTitan Pharma Stock (NASDAQ:TTNP) Dividends: History, Yield and DatesDecember 29, 2023 | finanznachrichten.deTitan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Reverse Stock Split and RatioDecember 28, 2023 | washingtonpost.comBarbie, the Titan submersible and everything else we Googled in 2023December 28, 2023 | finance.yahoo.comTitan Pharmaceuticals Announces Reverse Stock Split and RatioOctober 16, 2023 | finance.yahoo.comTitan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of DirectorsSeptember 18, 2023 | seekingalpha.comTitan Pharmaceuticals reports $9.5M private placement of convertible preferred stockSeptember 18, 2023 | finance.yahoo.comTitan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred StockAugust 28, 2023 | finance.yahoo.comUnveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive GuideAugust 13, 2023 | thestreet.comTitan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment ApprovalJuly 27, 2023 | finance.yahoo.comTitan Pharmaceuticals Announces Sale of Certain ProNeura AssetsJune 29, 2023 | usatoday.comPatents, lawsuits, safety concerns — then tragedy. A timeline of OceanGate's Titan sub.May 26, 2023 | finance.yahoo.comTTNP - Titan Pharmaceuticals, Inc.May 23, 2023 | sports.yahoo.comWatch: Prowling tiger bows to ‘titan herd’ of elephantsMarch 22, 2023 | seekingalpha.comTTNP Titan Pharmaceuticals, Inc.December 15, 2022 | finance.yahoo.comTitan Pharmaceuticals Provides Shareholder UpdateDecember 12, 2022 | nz.finance.yahoo.comTitan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.See More Headlines Receive TTNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/13/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TTNP CUSIPN/A CIK910267 Webwww.titanpharm.com Phone(650) 244-4990Fax650-244-4956Employees4Year Founded1992Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,570,000.00 Net Margins-2,014.71% Pretax Margin-5,760.46% Return on Equity-99.96% Return on Assets-77.58% Debt Debt-to-Equity RatioN/A Current Ratio11.83 Quick Ratio11.83 Sales & Book Value Annual Sales$180,000.00 Price / Sales35.09 Cash FlowN/A Price / Cash FlowN/A Book Value$8.82 per share Price / Book0.79Miscellaneous Outstanding Shares910,000Free Float686,000Market Cap$6.32 million OptionableOptionable Beta1.23 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. David Elliot Lazar (Age 33)CEO & Principal Financial Officer Comp: $1.42MDr. Katherine L. Beebe-DeVarney Ph.D. (Age 63)President, COO & Director Comp: $462kMr. Mike FritzNational Sales DirectorJennifer KiernanExecutive Assistant to CEO & Investor Communications CoordinatorJoe SchreiExecutive Director of Commercial OperationsKey CompetitorsBrickell BiotechNASDAQ:BBIMicrobot MedicalNASDAQ:MBOTCortexymeNASDAQ:CRTXZIVO BioscienceNASDAQ:ZIVOPharmaCyte BiotechNASDAQ:PMCBView All CompetitorsInsidersDavid E. LazarSold 169,445 sharesTotal: $4.17 M ($24.60/share)View All Insider Transactions TTNP Stock Analysis - Frequently Asked Questions How have TTNP shares performed in 2024? Titan Pharmaceuticals' stock was trading at $8.25 at the start of the year. Since then, TTNP stock has decreased by 15.9% and is now trading at $6.94. View the best growth stocks for 2024 here. When is Titan Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our TTNP earnings forecast. How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its quarterly earnings data on Wednesday, May, 15th. The specialty pharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter. Titan Pharmaceuticals had a negative trailing twelve-month return on equity of 99.96% and a negative net margin of 2,014.71%. When did Titan Pharmaceuticals' stock split? Titan Pharmaceuticals's stock reverse split before market open on Tuesday, January 9th 2024. The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Titan Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Organigram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI). How do I buy shares of Titan Pharmaceuticals? Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TTNP) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted t...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredAvoid These AI Stocks Like the Plague...Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.